Purpose-built for Biologics
Trained solely on biologics data, capturing modality-specific failure modes.
ABYX
ABYX
Only 6.7 % of Phase I biologic programs ever reach approval, an all-time low that keeps falling.
Immunogenicity drives a large share of attrition, with ADA implicated in 25 % of trial failures or withdrawals.
Each miss now pushes average R&D spend above $2.7 billion & over 10 years per launched drug.
Abyx exists to invert those numbers with sequence-level risk prediction and self-optimising, privacy-preserving trials.
Get StartedDrag-and-drop your candidate sequence and draft protocol.
Abyx auto-adds molecular, clinical & operational fingerprints.
Build a virtual twin of your trial to forecast ADA risk, PK/PD and more.
Interactive heat-maps trace each risk to clear redesign levers.
Trained solely on biologics data, capturing modality-specific failure modes.
Hospital data never leaves its node; differential-privacy noise keeps us ≤ 1.
Predict immunogenicity & adaptive trial success pre-IND. Slash time-to-clinic and de-risk fund-raising.
Book a Demo →
Host a federated node, keep data on-prem, and unlock continuous protocol optimisation.
Book a Demo →
Embed Abyx into your next Phase I/II study to hit recruitment targets faster and avoid surprises.
Book a Demo →